By Matt Olberding, Lincoln Journal Star
Lincoln-based biopharmaceutical company announced Wednesday that it has received a $20 million venture capital investment.
The Series A investment for Adjuvance Technologies came from Morningside Venture Investments Limited, a company with offices both in the U.S. and China that has invested in dozens of startups.
Adjuvance said the funds from the investment will be deployed to advance its first product, an agent that can be added to vaccines, through a proof-of-concept clinical trial.